Upgrade to SI Premium - Free Trial

Argus Upgrades Regeneron Pharma (REGN) to Buy, 'attractive entry point '

October 1, 2026 7:02 AM
Argus analyst Jasper Hellweg upgraded Regeneron Pharma (NASDAQ: REGN) from Hold to Buy with a price target of $850.00.The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Upgrades